863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort.
Saved in:
| Title: | 863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort. |
|---|---|
| Authors: | Cristea, M.C.1 (AUTHOR), Frankel, P.2 (AUTHOR), Synold, T.3 (AUTHOR), Stewart, D.B.1 (AUTHOR), Wang, E.1 (AUTHOR), Jung, A.4 (AUTHOR), Wilczynski, S.5 (AUTHOR), Tran, M.5 (AUTHOR), Konecny, G.E.6 (AUTHOR), Eng, M.7 (AUTHOR), Kilpatrick, L.8 (AUTHOR), Chen, Y-J.9 (AUTHOR), Glaser, S.9 (AUTHOR), Han, E.10 (AUTHOR), Dellinger, T.10 (AUTHOR), Hakim, A.10 (AUTHOR), Lee, S.10 (AUTHOR), Morgan, R.J.1 (AUTHOR), Rodriguez, L.10 (AUTHOR), Wakabayashi, M.10 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS639-S639. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 152695537 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Cristea%2C+M%2EC%2E%22">Cristea, M.C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Frankel%2C+P%2E%22">Frankel, P.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Synold%2C+T%2E%22">Synold, T.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stewart%2C+D%2EB%2E%22">Stewart, D.B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+E%2E%22">Wang, E.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jung%2C+A%2E%22">Jung, A.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wilczynski%2C+S%2E%22">Wilczynski, S.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tran%2C+M%2E%22">Tran, M.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Konecny%2C+G%2EE%2E%22">Konecny, G.E.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Eng%2C+M%2E%22">Eng, M.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kilpatrick%2C+L%2E%22">Kilpatrick, L.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+Y-J%2E%22">Chen, Y-J.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Glaser%2C+S%2E%22">Glaser, S.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Han%2C+E%2E%22">Han, E.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dellinger%2C+T%2E%22">Dellinger, T.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hakim%2C+A%2E%22">Hakim, A.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lee%2C+S%2E%22">Lee, S.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Morgan%2C+R%2EJ%2E%22">Morgan, R.J.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rodriguez%2C+L%2E%22">Rodriguez, L.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wakabayashi%2C+M%2E%22">Wakabayashi, M.</searchLink><relatesTo>10</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2020 Supplement 4, Vol. 31, pS639-S639. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152695537 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2020.08.1002 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S639 Titles: – TitleFull: 863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cristea, M.C. – PersonEntity: Name: NameFull: Frankel, P. – PersonEntity: Name: NameFull: Synold, T. – PersonEntity: Name: NameFull: Stewart, D.B. – PersonEntity: Name: NameFull: Wang, E. – PersonEntity: Name: NameFull: Jung, A. – PersonEntity: Name: NameFull: Wilczynski, S. – PersonEntity: Name: NameFull: Tran, M. – PersonEntity: Name: NameFull: Konecny, G.E. – PersonEntity: Name: NameFull: Eng, M. – PersonEntity: Name: NameFull: Kilpatrick, L. – PersonEntity: Name: NameFull: Chen, Y-J. – PersonEntity: Name: NameFull: Glaser, S. – PersonEntity: Name: NameFull: Han, E. – PersonEntity: Name: NameFull: Dellinger, T. – PersonEntity: Name: NameFull: Hakim, A. – PersonEntity: Name: NameFull: Lee, S. – PersonEntity: Name: NameFull: Morgan, R.J. – PersonEntity: Name: NameFull: Rodriguez, L. – PersonEntity: Name: NameFull: Wakabayashi, M. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2020 Supplement 4 Type: published Y: 2020 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 31 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
